Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 4/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 5/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63843 | 0.85 | PTGIR (0.38) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL52324 | 0.84 | ITGB3 (0.41) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL2633971 | 0.83 | — | — | |
| SCHEMBL31045282 | 0.72 | SIGMAR1 (0.51) | ABCB1SIGMAR1CYP3A4TSHRBTN3A1 | |
| SCHEMBL52346 | 0.70 | JAK2 (0.32) | CTSLCTSBCTSSCTSKCYP3A4 | |
| SCHEMBL1118425 | 0.70 | SIGMAR1 (0.42) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL17352069 | 0.70 | ITGB3 (0.44) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL63846 | 0.68 | ITGB3 (0.42) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL4972692 | 0.67 | ABCB1 (0.38) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL1117736 | 0.67 | DPP4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ITGB3 2078/4885ITGA2B 1968/4885CTSL 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.